Back to Journals » Drug Design, Development and Therapy » Volume 13

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities

Authors Flis S, Chojnacki T

Received 22 October 2018

Accepted for publication 9 January 2019

Published 8 March 2019 Volume 2019:13 Pages 825—843


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Jianbo Sun

Sylwia Flis,1 Tomasz Chojnacki2

1Department of Pharmacology, National Medicines Institute, 00-725 Warsaw, Poland; 2Department of Hematology, Military Institute of Medicine, 04-141 Warsaw, Poland

Abstract: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells. At the molecular level, the disorder results from t(9;22)(q34;q11) reciprocal translocation between chromosomes, which leads to the formation of an oncogenic BCR–ABL gene fusion. Instead of progress in the understanding of the molecular etiology of CML and the development of novel therapeutic strategies, clinicians still face many challenges in the effective treatment of patients. In this review, we discuss the pathways of diagnosis and treatment of patients, as well as the problems appearing in the course of disease development. We also briefly refer to several aspects regarding the current knowledge on the molecular basis of CML and new potential therapeutic targets.

Keywords: chronic myeloid leukemia, CML, BCR–ABL, tyrosine kinase inhibitors, TKI, TKI withdrawal, stem cells, autophagy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]